| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
(Received for publication, December 18, 1995)
From the Transforming growth factor
Volume 271, Number 29,
Issue of July 19, 1996
pp. 17366-17371
©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Type I
Receptor Contributes to the Malignancy of Human Colon Carcinoma
Cells
,
,
,
and
Department of Biochemistry and Molecular
Biology, Medical College of Ohio, Toledo, Ohio 43699, the
§ Department of Medicine and CWRU/Ireland Cancer Center, Case
Western Reserve University, Cleveland, Ohio 44106, the
¶ Department of Pharmacology, Duke University Medical
Center, Durham, North Carolina 27710, and the 
Department of
Pharmacology, University of Kentucky College of Medicine,
Lexington, Kentucky 40536
(TGF) type I (RI) and type II (RII) receptors are essential for
TGF signal transduction. A human colon carcinoma cell line,
designated GEO, is marginally responsive to TGF and expresses a low
level of RI mRNA relative to colon carcinoma cells, which are
highly responsive to TGF. Hence, the role of RI as a limiting factor
for TGF sensitivity and the contribution of low RI levels to the
malignant phenotype of GEO cells were examined. Stable transfection of
a tetracycline-regulatable rat RI cDNA increased
TGF1 binding to RI and resulted in increased growth
inhibition by exogenous TGF1. In contrast, although
stable transfection of an RII expression vector into the same GEO cells
increased TGF1 binding to RII, growth inhibition by
exogenous TGF1 was not altered. This indicated that the
low level of RI is a limiting factor for the growth-inhibitory effects
of TGF in GEO cells. RI-transfected cells were growth-arrested at a
lower saturation density than GEO control cells. They also showed
reduced growth and clonogenicity in plating efficiency and soft agarose
assays, whereas RII-transfected cells did not show any differences from
the NEO control cells in these assays. Tetracycline repressed RI
expression in transfected cells and reversed the reduction in plating
efficiency of RI-transfected clones, confirming that growth effects
were due to increased RI expression in transfected cells.
TGF1 neutralizing antibody stimulated the proliferation
of RI-transfected cells but had little effect on GEO control cells,
indicating that increased autocrine-negative TGF activity also
resulted from increased RI expression. Tumorigenicity in athymic nude
mice was significantly delayed in RI-transfected cells. These results
indicate that low RI expression can be a limiting factor for response
to exogenous TGF, as well as TGF autocrine-negative activity, and
that reduction of RI expression can contribute to malignant
progression.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Wang, L. Yang, J. Yang, K. Kuropatwinski, W. Wang, X.-Q. Liu, J. Hauser, and M. G. Brattain Transforming Growth Factor {beta} Induces Apoptosis through Repressing the Phosphoinositide 3-Kinase/AKT/Survivin Pathway in Colon Cancer Cells Cancer Res., May 1, 2008; 68(9): 3152 - 3160. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Xu and B. Pasche TGF-{beta} signaling alterations and susceptibility to colorectal cancer Hum. Mol. Genet., April 15, 2007; 16(R1): R14 - R20. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Wang, N. Sergina, T. C. Ko, J. Gong, and M. G. Brattain Autocrine and Exogenous Transforming Growth Factor {beta} Control Cell Cycle Inhibition through Pathways with Different Sensitivity J. Biol. Chem., September 17, 2004; 279(38): 40237 - 40244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ammanamanchi and M. G. Brattain Restoration of Transforming Growth Factor-{beta} Signaling through Receptor RI Induction by Histone Deacetylase Activity Inhibition in Breast Cancer Cells J. Biol. Chem., July 30, 2004; 279(31): 32620 - 32625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. B. Arnold, K. Ketterer, J. Kleeff, H. Friess, M. W. Buchler, and M. Korc Thioredoxin Is Downstream of Smad7 in a Pathway That Promotes Growth and Suppresses Cisplatin-Induced Apoptosis in Pancreatic Cancer Cancer Res., May 15, 2004; 64(10): 3599 - 3606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ammanamanchi, M. P. M. Tillekeratne, T. C. Ko, and M. G. Brattain Endogenous Control of Cell Cycle Progression by Autocrine Transforming Growth Factor {beta} in Breast Cancer Cells Cancer Res., April 1, 2004; 64(7): 2509 - 2515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. B. Buck, P. Fritz, J. Dippon, G. Zugmaier, and C. Knabbe Prognostic Significance of Transforming Growth Factor {beta} Receptor II in Estrogen Receptor-Negative Breast Cancer Patients Clin. Cancer Res., January 15, 2004; 10(2): 491 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. HUANG, T.-Y. LING, W.-F. TSENG, Y.-H. HUANG, F.-M. TANG, S. M. LEAL, and J. S. HUANG Cellular growth inhibition by IGFBP-3 and TGF-{beta}1 requires LRP-1 FASEB J, November 1, 2003; 17(14): 2068 - 2081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ammanamanchi, J. W. Freeman, and M. G. Brattain Acetylated Sp3 Is a Transcriptional Activator J. Biol. Chem., September 12, 2003; 278(37): 35775 - 35780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Chen, B. H. Davis, M. D. Sitrin, T. A. Brasitus, and M. Bissonnette Transforming growth factor-beta 1 signaling contributes to Caco-2 cell growth inhibition induced by 1,25(OH)2D3 Am J Physiol Gastrointest Liver Physiol, October 1, 2002; 283(4): G864 - G874. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-H. Kim, P. J. Wilder, J. Hou, T. Nowling, and A. Rizzino Activation of the Murine Type II Transforming Growth Factor-beta Receptor Gene. UP-REGULATION AND FUNCTION OF THE TRANSCRIPTION FACTOR Elf-3/Ert/Esx/Ese-1 J. Biol. Chem., May 10, 2002; 277(20): 17520 - 17530. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Adnane, E. Seijo, Z. Chen, F. Bizouarn, M. Leal, S. M. Sebti, and T. Munoz-Antonia RhoB, Not RhoA, Represses the Transcription of the Transforming Growth Factor beta Type II Receptor by a Mechanism Involving Activator Protein 1 J. Biol. Chem., March 1, 2002; 277(10): 8500 - 8507. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Yang, S. Kyo, M. Takatura, and L. Sun Autocrine Transforming Growth Factor {beta} Suppresses Telomerase Activity and Transcription of Human Telomerase Reverse Transcriptase in Human Cancer Cells Cell Growth Differ., February 1, 2001; 12(2): 119 - 127. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Isono, A. Mogyorosi, D. C. Han, B. B. Hoffman, and F. N. Ziyadeh Stimulation of TGF-beta type II receptor by high glucose in mouse mesangial cells and in diabetic kidney Am J Physiol Renal Physiol, May 1, 2000; 278(5): F830 - F838. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Pasche, P. Kolachana, K. Nafa, J. Satagopan, Y.-G. Chen, R. S. Lo, D. Brener, D. Yang, L. Kirstein, C. Oddoux, et al. T{{beta}}R-I(6A) Is a Candidate Tumor Susceptibility Allele Cancer Res., November 1, 1999; 59(22): 5678 - 5682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. P. Schiemann, W. M. Pfeifer, E. Levi, M. E. Kadin, and H. F. Lodish A Deletion in the Gene for Transforming Growth Factor beta Type I Receptor Abolishes Growth Regulation by Transforming Growth Factor beta in a Cutaneous T-Cell Lymphoma Blood, October 15, 1999; 94(8): 2854 - 2861. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Wang, L. Sun, E. Zborowska, J. K. V. Willson, J. Gong, J. Verraraghavan, and M. G. Brattain Control of Type II Transforming Growth Factor-beta Receptor Expression by Integrin Ligation J. Biol. Chem., April 30, 1999; 274(18): 12840 - 12847. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Won, H. Kim, E. J. Park, Y. Hong, S.-J. Kim, and Y. Yun Tumorigenicity of Mouse Thymoma Is Suppressed by Soluble Type II Transforming Growth Factor {beta} Receptor Therapy Cancer Res., March 1, 1999; 59(6): 1273 - 1277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Moustakas and C Stournaras Regulation of actin organisation by TGF-beta in H-ras-transformed fibroblasts J. Cell Sci., January 4, 1999; 112(8): 1169 - 1179. [Abstract] [PDF]
|
|
|
|
|
|
D. Jiang, H. Yang, J. K. V. Willson, J. Liang, L. E. Humphrey, E. Zborowska, D. Wang, J. Foster, R. Fan, and M. G. Brattain Autocrine Transforming Growth Factor alpha Provides a Growth Advantage to Malignant Cells by Facilitating Re-entry into the Cell Cycle from Suboptimal Growth States J. Biol. Chem., November 20, 1998; 273(47): 31471 - 31479. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ammanamanchi, S.-J. Kim, L.-Z. Sun, and M. G. Brattain Induction of Transforming Growth Factor-beta Receptor Type II Expression in Estrogen Receptor-positive Breast Cancer Cells through SP1 Activation by 5-Aza-2'-deoxycytidine J. Biol. Chem., June 26, 1998; 273(26): 16527 - 16534. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Sun and C. Chen Expression of Transforming Growth Factor beta Type III Receptor Suppresses Tumorigenicity of Human Breast Cancer MDA-MB-231 Cells J. Biol. Chem., October 3, 1997; 272(40): 25367 - 25372. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Chen, X.-F. Wang, and L. Sun Expression of Transforming Growth Factor beta (TGFbeta ) Type III Receptor Restores Autocrine TGFbeta 1 Activity in Human Breast Cancer MCF-7 Cells J. Biol. Chem., May 9, 1997; 272(19): 12862 - 12867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ammanamanchi and M. G. Brattain Sp3 Is a Transcriptional Repressor of Transforming Growth Factor-beta Receptors J. Biol. Chem., January 26, 2001; 276(5): 3348 - 3352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fanayan, S. M. Firth, A. J. Butt, and R. C. Baxter Growth Inhibition by Insulin-like Growth Factor-binding Protein-3 in T47D Breast Cancer Cells Requires Transforming Growth Factor-beta (TGF-beta ) and the Type II TGF-beta Receptor J. Biol. Chem., December 8, 2000; 275(50): 39146 - 39151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ammanamanchi and M. G. Brattain 5-AzaC Treatment Enhances Expression of Transforming Growth Factor-beta Receptors through Down-regulation of Sp3 J. Biol. Chem., August 24, 2001; 276(35): 32854 - 32859. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |
